Trial in Progress: QUINTESSENTIAL—a Phase 2 study of Arlocabtagene Autoleucel (arlo-cel) in Patients with relapsed/refractory Multiple Myeloma (RRMM)

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Ciara Louise Freeman, Nisha S. Joseph, Sarah M Larson, Omar Nadeem, Nikhil C. Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara K Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu
+8 more Svenja Groeneveld, Sarah E Johnston, Timothy Pulham, Sandy Wai Kuan Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina K. Patel
DOI: 10.1016/j.jtct.2025.12.282
Cited by: 0

Fields of Study & Subjects

Multiple Myeloma Research and Treatments CAR-T cell therapy research Protein Degradation and Inhibitors

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S205–S205
Publication date
1 February 2026
Language
EN